EMA proposes revision of its overarching biosimilars guideline
This article was originally published in Scrip
The European Medicines Agency is inviting feedback on plans to revise its so-called "overarching" guideline on biosimilars that has been in place since 2005. The proposed revision will take into account current practices companies use to develop these products.
You may also be interested in...
As companies undergo pharmacovigilance inspections from a growing multitude of regulatory authorities from around the globe, a senior pharmaceutical industry executive discusses how her company has been handling this complex and challenging task.
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.
The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.